Skip to main content
ADMA logo

ADMA · Adma Biologics, Inc.

Track ADMA — free
$13.38 +0.04 (+0.30%)
Market Cap
$2.96B
Shares
221.85M
Volume · Nov 20 249.93K Avg daily vol (3M) 3.2M

Price & Indicators

 

Key stats

Close
$13.34
Open
$13.50
Day range
$13.10–13.59
52-week closing range
$7.60–20.38
Average volume, 30 days
3.7M
Short interest
18.0M · 8.1% of shares · 7.1 days
Short volume, last session
17%
Last earnings
Nov 4, 2026
Latest filing
10-Q · Nov 4
Price history
Jan 2020 to Nov 2026

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue and net income rise sharply in third quarter

ADMA Biologics reported third-quarter revenue of 141,102 and net income of 49,884, both in thousands, versus 134,224 and 36,428 in the prior-year quarter. Cash and cash equivalents were 124,555, also in thousands.

Revenue $141.1M ▲ 5.1% Net income $49.88M ▲ 36.9% Diluted EPS $0.22 ▲ 46.7%
Read from the first part of this long document
4 source passages
ADMA BIOLOGICS, INC. AND SUBSIDIARIES | REVENUES | | 141,102 | 134,224 | | 379,990 | 371,010 | | NET INCOME | 49,884 | 36,428 | | 133,034 | 97,551 | | Cash<br>and cash equivalents | 124,555 | 87,630 | Open the document at this passage
Nov 4
Current report 8-K
Revenue grows as adjusted earnings outlook increases

ADMA Biologics reported 3Q 2026 total revenue of $141.1 million, up 5% year-over-year, and GAAP net income of $49.9 million, up 37%; it reiterated FY2026 revenue guidance of at least $530 million while increasing adjusted earnings expectations.

Financial results
5 source passages
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year Reiterates FY2026 Revenue Guidance; Increases Adjusted Earnings Outlook FY2026 total revenue expected to be at least $530 million ADMA Biologics, Inc. (Nasdaq: ADMA) Open the document at this passage
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $124.4M ▲ 2.0% Net income $37.82M ▲ 10.5% Diluted EPS $0.16 ▲ 14.3%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$519.15M
Trailing 12 months
Net income (TTM)
$182.41M
Trailing 12 months
Revenue growth YoY
+5.1%
Year over year
Operating margin
46.5%
Trailing 12 months
P / E (TTM)
17.3
Trailing earnings · reciprocal yield 5.8%
FCF yield
4.5%
TTM · current market cap
Return on invested capital
36.8%
Trailing 12 months
Net cash
−$71.30M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-7.7%
Year over year · fewer shares
Price change (1Y)
-16.4%
Trailing year
Short interest
8.1%
Latest settlement · 7.1 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. ADMA reported Q2 2026 total revenue of $124.4 million with ASCENIV revenue up 24% year-over-year to $102.9 million, while BIVIGAM revenue declined 49% year-over-year to $19.4 million (though stabilizing sequentially). The company reiterated its full-year 2026 guidance, repurchased 7.1 million shares during the quarter, and continued to advance SG-001 toward a year-end pre-IND submission.

Bullish
  • + Gross margin expanded to 69% in Q2 2026 from 55% in the prior-year period, driven by ASCENIV mix and yield-enhanced manufacturing.
  • + Adjusted EBITDA grew 22% year-over-year to $61.8 million and GAAP net income rose 11% to $37.8 million in Q2 2026.
  • + Company repurchased 7.1 million shares in Q2 (13.8 million YTD, ~5.3% of shares outstanding) and remains on track to complete its $200 million-plus 2026 share repurchase target.
Bearish
  • − BIVIGAM revenue declined 49% year-over-year to $19.4 million in Q2 2026 amid continued competitive pricing and supply pressure in the U.S. standard immunoglobulin market.
  • − Effective tax rate rose to 24.7% in Q2 2026 from 14.7% in the prior-year period, an increase of approximately 10 percentage points.
  • − R&D expenses increased to $6.0 million in Q2 2026 from $1.0 million in the prior-year period, and are expected to step up again in Q4 for SG-001 conformance lot manufacturing.
  • − SG&A expenses rose to $26.7 million in Q2 2026 from $22.2 million in the prior-year period, driven partly by higher professional and consulting fees associated with ongoing legal and related matters.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Strong Buy
50 / 200-day cross Golden cross
Price vs 200-day avg +25%
above
Price vs 50-day avg +22%
above
RSI (14) 65
neutral
MACD trend Positive
52-week position 45%
mid-range
Momentum
relative strength
Strong
1-month return +22%
trailing
6-month return +69%
trailing
YTD return −27%
this year
Relative strength +74%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) Golden cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +42 funds added
Insider flow Distributing
Net -$139.2K over 90 days · 100% sells
Short interest Falling
8.13% of shares out · ▼ -7.6% MoM · 7.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
333 holders — mid 3-yr range
Squeeze score 75
high risk · 0–100
Fundamentals
Excellent
Revenue growth +44%
Y/Y
Gross margin 693%
contracting
EPS growth −26%
Y/Y
Free cash flow $27.8M
Valuation P/E 17.3
below peers
Buyback $312.8M
remaining
Balance sheet $15.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 59%
annualized · 1-yr
Max drawdown −63%
past year
ATR 4.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 6
Latest guidance · from the 8-K filed Nov 4, 2026
FY2026 total revenue · FY2026 at least $530M
prior FY $510.17M midpoint +3.9% Y/Y
FY2026 Adjusted Net Income · FY2026 Non-GAAP at least $180M
FY2026 Adjusted EBITDA · FY2026 Non-GAAP at least $275M
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted net income · full year 2026 $170M – $200M
Adjusted EBITDA · full year 2026 $265M – $300M
Prior guidance period ended · from the 8-K filed Jan 12, 2026
Adjusted EBITDA margin · FY 2025 46%
Guided vs delivered · last 6 settled
Total revenue fiscal year 2025
guided $510M
$510.17M Beat +0.0%
Total revenue FY 2024
guided at least $400M
$426.45M In line
Total revenues FY 2023
guided at least $250M
$258.22M In line
Total revenue fourth quarter 2022
guided $48M – $50M
$49.98M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 2 · 4
50 / 200-day cross
Golden cross Bullish
Price vs 200-day avg
+25% Bullish
Price vs 50-day avg
+22% Bullish
RSI (14)
65 Neutral
MACD trend
Positive Bullish
52-week position
45% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) Golden cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +42 funds added
Insider flow Distributing
Net -$139.2K over 90 days · 100% sells
Short interest Falling
8.13% of shares out · ▼ -7.6% MoM · 7.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
333 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $8 Now $13 · 45% Range high $20
vs 200-day avg +25% vs 50-day avg +22% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $121.5M six months ended June 30, 2026 —
Adjusted Net Income non-GAAP $79.6M six months ended June 30, 2026 —
ASCENIV revenue growth 26% Six months ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ADMA
Adma Biologics, Inc.
this stock
$2.96B -26.9% +43.9% 17.3 8.1%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
333
% held
90.5%
Net QoQ
-2.4M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
286
View
Short & Settlement
Short Interest Falling
Shares short
18.0M
Days to cover
7.1d
Change
-1.5M sh
View
Short Volume
Short vol %
17%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
480
Value
$5.6K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
36.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$139.2K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$510.2M
Net income (FY)
$146.9M
EPS diluted
$0.60
View
Buybacks
Authorized
$500.0M
Remaining
$312.8M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
17

ADMA Biologics reported third-quarter revenue of 141,102 and net income of 49,884, both in thousands, versus 134,224 and 36,428 in the prior-year quarter. Cash and cash equivalents were 124,555, also in thousands.

View
Proposed Sales
Value
$136.8K
Shares
10.0K
Filed
Nov 16, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
ADMA Biologics Reports Third Quar…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
ADMA +0.8% +21.8% +68.9% +16.9% -26.9%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +6.2% +28.1% +74.5% +22.2% -31.8%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
$500.00M
Spent (derived)
$187.20M
Remaining
$312.80M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1368514 CUSIP 000899104 13F (30d) 333 filings 305 filers Visit website Investor relations